Portal Diabetes announced today that it received FDA breakthrough device designation for its implantable insulin pump system. The Westfield, Indiana–based company can now begin a Phase 1 study to evaluate its proprietary, temperature-stable insulin. It aims to deliver a functional cure for type 1 diabetes. Portal Diabetes developed its system, called the Portal Pump, to […]
Drug-Device Combinations
Dexcom beats Street in Q4 on 13% sales growth
Dexcom (NSDQ:DXCM) shares ticked up after hours today on fourth-quarter results that came in ahead of the consensus forecast. Shares of DXCM rose 1% to $65.70 apiece in post-market trading today. The San Diego-based continuous glucose monitor (CGM) maker reported profits of $267.3 million. That equals 68¢ per share on sales of $1.259 billion for […]
Embecta names CEO Kurdikar as new board chair, picks new lead independent director
Embecta (Nasdaq:EMBC) announced today that its board of directors elected the company’s CEO, Devdatt “Dev” Kurdikar, as chair. The Parsippany, New Jersey-based BD Diabetes spinoff also named Dr. Claire Pomeroy as lead independent director. Both appointments go into effect immediately. These changes follow the retirement of David Melcher, who previously served as non-executive chair of the […]
LifeScan, i-SENS partner to launch CGM platform
LifeScan announced today that it partnered with i-SENS to launch a continuous glucose monitoring (CGM) system. Malvern, Pennsylvania–based LifeScan develops the OneTouch Bluetooth-connected blood glucose meter and mobile diabetes app. It aims to provide simplicity, accuracy and trust in diabetes management. i-SENS, a global in vitro diagnostics company, researches, develops and produces products leveraging advanced […]
MannKind enrolls first patient in study of inhaled insulin for pediatric type 1 diabetes
MannKind (Nasdaq:MNKD) announced today that it enrolled the first patient in the INHALE-1ST study of its Afrezza inhaled insulin. INHALE-1ST evaluates the initiation of Afrezza inhalation powder therapy shortly after type 1 diabetes diagnosis in pediatric patients. Afrezza (insulin human) inhalation powder is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical […]
Modular Medical hits validation milestone, targets commercial launch for insulin patch pump soon
Modular Medical (Nasdaq:MODD) announced that it started the production of validation lots for its Pivot tubeless insulin patch pump. The lots include the next-generation Pivot pump’s disposable cartridge and infusion set. With the milestone, the San Diego-based company said it remains on track for a commercial launch in the first quarter of 2026, subject to […]
Insulet launches Omnipod 5, Omnipod Discover in the Middle East
Insulet (Nasdaq:PODD) announced today that it launched its Omnipod 5 and Omnipod Discover offerings in the Middle East. The company made its automated insulin delivery system available in Saudi Arabia, Kuwait, Qatar and the United Arab Emirates (UAE). Omnipod 5 became the world’s first available tubeless, wearable, automated insulin delivery system when it received FDA […]
Embecta stock ticks up on Street-beating Q1
Embecta (Nasdaq:EMBC) shares got a boost today on first-quarter results that beat the consensus Wall Street forecast. Shares of EMBC rose 6.5% to $12.09 apiece in early-morning trading today. The Parsippany, New Jersey-based BD Diabetes spinoff reported profits of $44.1 million. That equals 74¢ per share on sales of $261.2 million for the three months ended […]
Beta Bionics receives FDA warning letter
Beta Bionics (Nasdaq:BBNX) recently disclosed the receipt of a warning letter from the FDA following an inspection. An FDA inspection of the company’s Irvine, California, facility from June 9, 2025, through June 26, 2025, led to the warning letter. In the letter, the FDA outlined deficiencies in the automated insulin delivery system maker’s response letters […]
Dexcom adds enhanced smart meal logging feature to Stelo CGM
Dexcom (NSDQ:DXCM) announced today that it plans to launch an advanced AI-enabled enhancement to its Stelo over-the-counter CGM. The new enhancements to the continuous glucose monitor (CGM) aim to transform how users understand their glucose health. Dexcom said it hopes to help Stelo users achieve their long-term health goals through the updates. It plans to […]










